Bolar and Vitarine sued again
Executive Summary
Generic firms sued in class action filed in Pennsylvania federal court by SmithKline Beecham shareholders, Bolar disclosed June 27. Complaint alleges violations of racketeering and federal securities statutes "in connection with allegations that Bolar and Vitarine submitted false or misleading information to FDA in gaining approval" of generic versions of Dyazide, Bolar notes. Smith-Kline Beecham also filed a complaint against the two firms and Schein alleging unfair competition ("The Pink Sheet" June 18, T&G-8).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.